In Brief: Maxxim, Dade sole-source deals
This article was originally published in The Gray Sheet
Executive Summary
Maxxim, Dade sole-source deals: Maxxim Medical wins contract as exclusive provider of procedure packs and related services to 86 institutions in University Health Systems' group purchasing programs. The two-year agreement, which goes into effect Jan. 1, 1996 and has a three-year extension option, could grow from a base of $23 mil. in sales to $80 mil. per year by the end of the contract. Maxxim agrees to work with UHC to reduce costs through supply chain management and "through standardization, consumption reviews, and influencing use"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.